{'fraction_non_alphanumeric': 0.01694915254237288, 'fraction_numerical': 0.004842615012106538, 'mean_word_length': 4.9496402877697845, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
ADHD Medications: Cardiovascular Safety in Adults

In 2006 the FDA issued a public health advisory about the risk of persistent pulmonary hypertension of the newborn (PPHN) when mothers received SSRIs during pregnancy. PPHN is a condition that occurs when newborns do not adapt to breathing outside of the womb. The warning was based on a single study, and results of subsequent studies have been inconsistent. After review of the newer evidence, the FDA has decided that no conclusion can be reached at this time about the possible link between SSRI use in pregnancy and PPHN. Newborns with PPHN may require intensive care and mechanical ventilation. Severe PPHN can lead to organ damage, brain damage, and death. The FDA recommends that clinicians not change their current practices for treating depression during pregnancy.